Wound Healing made easier and faster with Corplex

Corplex offers a robust matrix and protective barrier to the injured or affected area at the time of wound remodeling.

FREMONT, CA: StimLabs, one of the leaders in regenerative technologies and products transforming patient care, releases Corplex, the first among the two umbilical cord-derived products launching in the current year.

Corplex, a dehydrated human umbilical cord tissue, is provided in a sheet format as a wound covering or barrier membrane over chronic and acute wounds. The Corplex allograft is built to retain both the epithelial layer as well as the hyaluronan-rich Wharton's Jelly, largely concentrated in extracellular matrix components like collagen and glycosaminoglycans. The aforementioned proprietary approach enhances the retention of key extracellular matrix components, including glycosaminoglycans, collagens, and proteoglycans that offer a robust matrix and protective barrier.

One of the StimLabs' long-term ambitions is to create solutions to address the more precise requirements of each wound. Conventionally, StimLabs has used Revita, the first complete thickness amniotic tissue allograft, for several acute and chronic wound cases. Corplex offers a better alternative for acute and chronic wounds where a more hydrophilic and thicker product is warranted.

According to a senior leader at StimLabs, the firm is dedicated to providing more targeted approaches to impact healing via ease of use, accessibility, and effectiveness, to ultimately enhance care outcomes. The company is working diligently towards ensuring that such patent-pending products and processes is another step towards improved medical outcomes. Thus, the firm continues pushing its product portfolio boundaries to more effectively address the needs of patients as well as the providers.

StimLabs, LLC, was established in 2015 with an aim to advance the state of regenerative medicine. Within a year of its inception, StimLabs developed and certified an ISO Class 7 cleanroom facility, conceptualized and released a suite of placental-derived products, and developed a massive product pipeline across a wide range of clinical applications.